Dr. Lynch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3401 Civic Center Blvd
Childrens Hospital of Philadelphia Neurology
Philadelphia, PA 19104Phone+1 215-590-1719Fax+1 215-590-1771
Education & Training
Johns Hopkins University School of MedicineClass of 1988
Certifications & Licensure
FL State Medical License 2021 - Present
MD State Medical License 2022 - 2024
NY State Medical License 2021 - 2024
PA State Medical License 1990 - 2024
VA State Medical License 2021 - 2024
NC State Medical License 2020 - 2022
OH State Medical License 1990 - 2014- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Start of enrollment: 2007 Dec 01
- Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Start of enrollment: 2008 Jul 01
- Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Start of enrollment: 2009 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Insulin sensitivity and insulin secretion in adults with Friedreich's Ataxia: the role of skeletal muscle.Jaclyn Tamaroff, Sara Nguyen, Neil E Wilson, Darko Stefanovski, Rui Xiao
The Journal of Clinical Endocrinology and Metabolism. 2024-08-07 - Autoimmune 'secondary synaptopathies': do NMDAR antibodies cause a primary extra-synaptopathy?Meng Zhao, David R Lynch, Sarosh R Irani
Brain. 2024-08-01 - 1 citationsNAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich's Ataxia.Caroline E Perry, Sarah M Halawani, Sarmistha Mukherjee, Lucie V Ngaba, Melissa Lieu
JCI Insight. 2024-07-18
Press Mentions
Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)September 15th, 2021- Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development ProgramsAugust 9th, 2021
Could Statins Ease Deadly Heart Condition in Friedreich’s Ataxia?April 17th, 2018
Grant Support
- Nicotinic-Glutamatergic Interactions In Axonal DevelopmentNational Institute Of Neurological Disorders And Stroke2011
- Regulation Of NMDA Receptors In Excitotoxicity By Calpain And FYNNational Institute Of Neurological Disorders And Stroke2008–2011
- Defining The Epitope In Antinmda Receptor EncephalitisNational Institute Of Neurological Disorders And Stroke2009–2010
- Regulation Of NMDA Receptors In Excitotoxicity By Calpain And FYNNational Institute Of Neurological Disorders And Stroke2007
- Calpain Mediated Cleavage Of NR2 In ExcitotoxicityNational Institute Of Neurological Disorders And Stroke2004–2006
- Calpain Mediated Cleavage Of NR2 In ExcitotoxicityNational Institute Of Neurological Disorders And Stroke2003
- NMDA Receptors, Protein Kinase C, And ExcitotoxicityNational Institute Of Neurological Disorders And Stroke1999–2002
- PCP And The NMDA ReceptorNational Institute On Drug Abuse1996–1999
- Biochemical Approach To NMDA Receptors &ExcitotoxicityNational Institute Of Neurological Disorders And Stroke1995–1999
- NMDA Receptors--Biochemical Definition And Pharmacological CharacterizationEunice Kennedy Shriver National Institute Of Child Health &Human Development1995–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
